LY2880070

· Esperas Pharma Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY2880070, covering 2025-05-02 to 2025-05-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer [Phase 1, Phase 2]